The company's lead product candidate, KPI-012, is in Phase 2b clinical trial for treatment of persistent corneal epithelial defects and limbal stem cell deficiency and other rare corneal diseases. Its preclinical development product consists of KPI-014 for the treatment of rare inherited retinal diseases. The company maintains a focused pipeline on ophthalmic indications with specialized drug delivery technology.
Cyborg Score Rationale
The company has a market cap of approximately $10.3M, indicating severe capital constraints. The stock has declined 94.42% over the past year, reflecting significant shareholder value destruction. As a pre-revenue clinical-stage company with minimal resources, execution risk is extreme.
Top Insights
Market cap of $10.3M indicates severe capital constraints for a clinical-stage biotech company
Stock has declined 94.42% over the past year with extreme volatility (52-week range $0.36 to $20.60)
Company rebranded from Kala Pharmaceuticals to KALA BIO in August 2023 as part of strategic repositioning
Extremely lean operations with only 38 employees as of Feb 2026
Named Competitors
Ophthalmic Portfolio — Established ophthalmic pharmaceutical portfolio with broad disease coverage
Retinal Disease Focus — Large pharma with inherited retinal disease programs